Combination high-dose interleukin-2 and nivolumab for programmed cell death-1 refractory metastatic melanoma: a case series

BACKGROUND: Therapeutic options are needed for metastatic melanoma refractory to therapies directed against programmed cell death-1. High-dose interleukin-2 has the potential to overcome programmed cell death-1 resistance. CASE PRESENTATION: We report three consecutive Caucasian patients, two female...

Descripción completa

Detalles Bibliográficos
Autores principales: Nikanjam, Mina, Mullen, Jaren, Yacoub, Carol, Daniels, Gregory A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429475/
https://www.ncbi.nlm.nih.gov/pubmed/36045435
http://dx.doi.org/10.1186/s13256-022-03536-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429475/
https://www.ncbi.nlm.nih.gov/pubmed/36045435
http://dx.doi.org/10.1186/s13256-022-03536-y

Ejemplares similares